A5029602752- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- CAR-T cell therapy research
- Bone Tumor Diagnosis and Treatments
- Immunotherapy and Immune Responses
- Drug-Induced Hepatotoxicity and Protection
- Oral and Maxillofacial Pathology
- Cell Adhesion Molecules Research
- Pharmacogenetics and Drug Metabolism
- Ubiquitin and proteasome pathways
- Computational Drug Discovery Methods
Leiden University Medical Center
2021-2024
Centre for Human Drug Research
2024
Leiden University
2024
Chordomas are rare cancers from the axial skeleton which present a challenging clinical management with limited treatment options due to their anatomical location. In recent years, few trials demonstrated that chordomas can respond immunotherapy. However, an in-depth portrayal of chordoma immunity and its association parameters is still lacking.
Myxofibrosarcoma and undifferentiated soft tissue sarcoma (USTS) are genetically complex sarcomas with distinct morphological features. Treatment typically involves surgery, often combined neoadjuvant chemo- or radiotherapy. To better understand the immunobiology of these its associations treatment response prognosis, we performed transcriptomic immunophenotypic profiling. RNA sequencing was on 13 USTS 10 myxofibrosarcomas immunological profiles were compared data from The Cancer Genome...
Abstract Background and Aims Drug‐induced liver injury (DILI) is one of the most frequent reasons for failure drugs in clinical trials or market withdrawal. Early assessment DILI risk remains a major challenge during drug development. Here, we present mechanism‐based weight‐of‐evidence approach able to identify certain candidate compounds with liabilities due mitochondrial toxicity. Methods A total 1587 FDA‐approved 378 kinase inhibitors were screened cellular stress response activation...
Osteosarcoma is the most common primary bone sarcoma. About 50% of patients develop metastatic disease and their 5-year survival lingers at around 20%-30%. T cell checkpoint blockade immunotherapies have revolutionised cancer treatment in last decade, but impact remains limited osteosarcoma. In order to reveal potentially novel immunotherapeutic strategies for advanced osteosarcoma, we conducted an immunogenomic characterisation a unique sample set comprising 30 osteosarcoma samples from...
Abstract Chordomas are cancers from the axial skeleton presenting immunological hallmarks of unknown significance. In recent years, some clinical trials demonstrated that chordomas can respond to immunotherapy. We present a comprehensive characterisation features 76 through application multimodal approach comprising transcriptional profiling, multidimensional immunophenotyping and TCR profiling. generally presented an immune “hot” microenvironment in comparison other sarcomas, as indicated...